Igm Biosciences
IGM Biosciences, Inc. is a biotechnology company focused on developing innovative therapies based on its proprietary IgM antibody platform. Founded in 2010, the company operates primarily in the biopharmaceutical sector, concentrating on the design and commercialization of novel therapeutics for the treatment of various cancers and autoimmune diseases. Its core products include IGM-2323, an investigational IgM antibody designed to target specific cancer cells, as well as other pipeline candidates aimed at addressing unmet medical needs.